Svenja Tonn
Hamburg, HH, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Correction: Biglycan-driven risk stratification in ZFTA-RELA fusion supratentorial ependymomas through transcriptome profiling.
Journal: Acta neuropathologica communications
Published: August 21, 2025
Salvage therapies for first relapse of SHH medulloblastoma in early childhood.
Journal: Neuro-oncology
Published: April 05, 2025
Impact of molecular classification on prognosis in children and adolescents with spinal ependymoma: Results from the HIT-MED database.
Journal: Neuro-oncology advances
Published: December 23, 2024
Biglycan-driven risk stratification in ZFTA-RELA fusion supratentorial ependymomas through transcriptome profiling.
Journal: Acta neuropathologica communications
Published: October 23, 2024
Transcriptome analysis stratifies second-generation non-WNT/non-SHH medulloblastoma subgroups into clinically tractable subtypes.
Journal: Acta neuropathologica
Published: March 06, 2023
Risk prediction in early childhood sonic hedgehog medulloblastoma treated with radiation-avoiding chemotherapy: Evidence for more than 2 subgroups.
Journal: Neuro-oncology
Published: January 30, 2023
Outcomes of Infants and Young Children With Relapsed Medulloblastoma After Initial Craniospinal Irradiation-Sparing Approaches: An International Cohort Study.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: December 22, 2022
Gene expression profiling of Group 3 medulloblastomas defines a clinically tractable stratification based on KIRREL2 expression.
Journal: Acta neuropathologica
Published: May 13, 2022
Showing 1-8 of 8
Last Updated: 09/26/2026